- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03378011
UVA1 Phototherapy in Acral Vitiligo
December 17, 2017 updated by: Maha Fathy Elmasry, Cairo University
The Role of Long Wavelength UVA1 Phototherapy in Acral Vitiligo
evaluate the effect of UVA1 phototherapy in the treatment of acral vitiligo.
Study Overview
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cairo, Egypt
- Maha Fathy Elmasry
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years and older (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with acral vitiligo.
- Patients more than 12 years old.
Exclusion Criteria:
- Patients less than 12 years old.
- Patients with any other skin diseases or autoimmune diseases.
- Patients taking medical treatment or phototherapy for vitiligo.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: UVA1 phototherapy
UVA1 phototherapy in acral vitiligo
|
phototherapy either UVA1 or topical PUVA on acral vitiligo
|
ACTIVE_COMPARATOR: Topical PUVA
Topical PUVA in acral vitiligo
|
phototherapy either UVA1 or topical PUVA on acral vitiligo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
effect of medium dose UVA1 phototherapy in treatment of acral vitiligo
Time Frame: 1 year
|
effect of medium dose UVA1 phototherapy in treatment of acral vitiligo using point counting and vitiligo area severity index (VASI) score
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 1, 2015
Primary Completion (ACTUAL)
November 1, 2016
Study Completion (ACTUAL)
November 1, 2016
Study Registration Dates
First Submitted
December 8, 2017
First Submitted That Met QC Criteria
December 17, 2017
First Posted (ACTUAL)
December 19, 2017
Study Record Updates
Last Update Posted (ACTUAL)
December 19, 2017
Last Update Submitted That Met QC Criteria
December 17, 2017
Last Verified
December 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Dermatology 3
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acral Vitiligo
-
PfizerRecruitingStable Nonsegmental Vitiligo | Active Nonsegmental VitiligoUnited States, Spain, Australia, Mexico, Canada, China, Japan, Italy, Turkey, Korea, Republic of, Germany, South Africa, Poland, United Kingdom, Bulgaria
-
PfizerRecruitingStable Nonsegmental Vitiligo | Active Nonsegmental VitiligoJapan, Canada, China, United States
-
Innovent Biologics (Suzhou) Co. Ltd.TerminatedAcral Melanoma That Has Been Removed by SurgeryChina
-
Fundació Institut de Recerca de l'Hospital de la...Completed
-
Incyte CorporationRecruitingNonSegmental VitiligoGermany, United States, Italy, Poland, Canada, France, Bulgaria, Hungary, United Kingdom
-
Incyte CorporationCompletedNonSegmental VitiligoUnited States, Canada
-
Cairo UniversitySuspended
-
Assiut UniversityUnknown
-
University of TorontoCanadian Interdisciplinary Network Complementary & Alternative Medicine ResearchCompleted
-
University Hospital, GhentNovartisCompletedVitiligo VulgarisBelgium
Clinical Trials on phototherapy
-
University of Nove de JulhoCompletedPhotobiomodulation In the Masseter and Temporal In Patients With Temporomandibular Joint DysfunctionTemporomandibular Disorder
-
University of ZurichCompletedPsoriasis | EczemaSwitzerland
-
University of Nove de JulhoUnknownTemporomandibular Disorder.Brazil
-
Nathalie CharpakHospital Universitario San Ignacio; Pontificia Universidad JaverianaCompletedPhototherapy | Jaundice, NeonatalColombia
-
Shin Kong Wu Ho-Su Memorial HospitalCompletedBrief Description of Focus of Study InsteadTaiwan
-
Istituti Fisioterapici OspitalieriUnknown
-
University of Nove de JulhoFundação de Amparo à Pesquisa do Estado de São PauloCompletedExcessive Physical Exercise, UnspecifiedBrazil
-
University of MinnesotaThrasher Research FundCompletedFiltered Sunlight Phototherapy to Treat Significant Jaundice: Safety and Efficacy in Neonates (FSPT)Jaundice, NeonatalNigeria
-
University of MinnesotaThrasher Research FundCompletedJaundice, NeonatalNigeria
-
Henry Ford Health SystemWithdrawn